COMMUNIQUÉS West-GlobeNewswire

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

31/10/2017 - 08:00

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

31/10/2017 - 08:00

PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and Conshohocken, US, 31 October 2017) [...]

Verona Pharma to Present at Two Upcoming Investor Conferences

31/10/2017 - 07:55

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

DBV Technologies Reports September 30, 2017 Cash Position

31/10/2017 - 07:30

Press Release Montrouge, France, October 31, 2017 DBV Technologies Reports September 30, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and [...]

DBV Technologies publie sa position de trésorerie au 30 septembre 2017

31/10/2017 - 07:30

Communiqué de Presse Montrouge, France, le 31 octobre 2017, 7h30 CET DBV Technologies publie sa position de trésorerie au 30 septembre 2017 DBV Technologies, (Euronext: DBV - ISIN : FR0010417345 - NASDAQ : DBVT), [...]

Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor

31/10/2017 - 07:15

Basel, Switzerland, October 31, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea [...]

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

31/10/2017 - 07:15

Media release (PDF) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017

31/10/2017 - 07:00

ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all publicly held registered shares of Actelion Ltd ( Actelion ) with [...]

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

31/10/2017 - 07:00

PRESS RELEASE TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure Leuven (BELGIUM) - October 31, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]

ABLYNX CLOSES ON UNDERWRITERS' OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING

30/10/2017 - 21:30

REGULATED INFORMATION GHENT, Belgium, 30 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]

Nightstar Therapeutics to Participate in Multiple Conferences in November

30/10/2017 - 21:05

LEXINGTON, Mass. and LONDON, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced [...]

Diaxonhit : Résultats semestriels 2017, Bénéfices très positifs de l'acquisition de Capforce Plus

30/10/2017 - 19:02

DIAXONHIT - Résultats semestriels 2017 Premiers bénéfices très positifs de l'acquisition de Capforce Plus Réussite de la première phase d'intégration Accélération de la dynamique commerciale Objectifs opérationnels [...]

Exercise of over-allotment option in relation to the IPO of Terveystalo Plc and termination of the stabilization period

30/10/2017 - 18:00

TERVEYSTALO PLC STOCK EXCHANGE RELEASE 30 October, 2017 at 19:00 EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL [...]

NANOBIOTIX lance une augmentation de capital par construction accelerée d'un livre d'ordre

30/10/2017 - 17:47

NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D'UN LIVRE D'ORDRE Paris, France, et Cambridge, Massachusetts, USA, 30 octobre 2017 - NANOBIOTIX (la « Société ») (Euronext: NANO - ISIN: [...]

NANOBIOTIX launches capital increase by means of an accelerated bookbuild offering

30/10/2017 - 17:47

NANOBIOTIX LAUNCHES CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING Paris, France and Cambridge, Massachusetts, October 30, 2017 - NANOBIOTIX (the " Company ") (Euronext: NANO - ISIN: FR0011341205), a [...]

Ascom wins order to supply advanced nurse call solution for elderly care facilities in Norway

30/10/2017 - 17:30

BAAR, Switzerland, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW) secures a long term contract with the Drammen municipality in Norway to modernize and improve the communication infrastructure of its elderly care [...]

Ossur Hf : Transactions in relation to share buyback program

30/10/2017 - 17:00

Announcement from Össur hf. No. 79/2017 Reykjavík, 30 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Ossur Hf: Insider trading

30/10/2017 - 15:26

Announcement Össur hf. N o. 78/2017 Viðskipti með eigin bréf/ transaction in own financial instruments Nafn/Name: Össur hf. Dagsetning viðskipta/Date of transaction: 30 October 2017 Kaup eða sala/Buy or Sell: Sell [...]

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

30/10/2017 - 15:00

FIT Biotech Oy Company release October 30, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]